However, the reported side effects and therapeutic inefficacy promote the development of new therapeutic alternatives, such as glucagon-like peptide-1 (GLP1) receptor agonists and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, to restore insulin secretion for the treatment of T2DM [103]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.